Inhibikase Therapeutics, Inc. Common Stock (IKT) is a publicly traded Healthcare sector company. As of May 21, 2026, IKT trades at $1.72 with a market cap of $212.57M and a P/E ratio of -3.80. IKT moved +7.64% today. Year to date, IKT is -16.42%; over the trailing twelve months it is -15.58%. Its 52-week range spans $1.13 to $4.20. Analyst consensus is strong buy with an average price target of $6.20. Rallies surfaces IKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Inhibikase Reports $170.4M Cash, EMA FAST-EU Greenlight for Phase 3 in 16 Countries: Inhibikase Therapeutics enrolled the first registrational IMPROVE-PAH patient after securing 16 country approvals including EMA FAST-EU clearance. The company ended Q1 with $170.4 million cash and reported a $16.4 million net loss as Phase 3 trial activations advance globally.
| Metric | Value |
|---|---|
| Price | $1.72 |
| Market Cap | $212.57M |
| P/E Ratio | -3.80 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.20 |
| 52-Week Low | $1.13 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.72M |
| Net Income | $-50.96M |
| Gross Margin | 0.00% |
5 analysts cover IKT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.20.